Skip to main content
Premium Trial:

Request an Annual Quote

ABI/MDS Sciex, Pfizer, and Sound Analytics to Develop New ADME Software

This update clarifies the title of Laura Lauman, who is president of ABI's proteomics and small molecule division.
NEW YORK (GenomeWeb News) — Applied Biosystems, MDS Sciex, Pfizer, and Sound Analytics plan to develop software that will work with high-throughput automation technology to improve compound analysis.
The technology will focus on improving techniques for analyzing absorption, distribution, metabolism, and excretion. 
By improving the “timeliness and accuracy” of information drawn from ADME testing, ABI said, the new software would increase the efficiency of the pre-clinical drug-development process. 
Pfizer R&D Director Cornelis Hop said that because a swift analysis of the characteristics of compounds is a “major challenge in drug discovery,” drug makers “need a new approach that delivers rapid turnaround of ADME-related assay data.”
Laura Lauman, president of ABI's proteomics and small molecule division, said that the end goal of the project is to help drug makers kill bad compounds early and often.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.